St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Myelodysplastic syndromes (MDS) are a group of disorders in which the bone marrow does not make enough healthy blood cells. Bone marrow is the spongy material inside bones. It contains stem cells that become red blood cells, white blood cells, and platelets.
MDS signs and symptoms are related to a decrease in healthy blood cells. These include:
Causes of MDS can include previous aplastic anemia or a history of chemotherapy or radiation treatment for other cancers. MDS may also be linked to genetic conditions, such as inherited bone marrow failure syndromes and MDS predisposition syndromes. Often, the cause of MDS in children is not known.
Pediatric MDS is rare. About 4 in every 1 million children are diagnosed with MDS each year. There are 2 main types of MDS in children: refractory cytopenia of childhood (RCC) and MDS with excess blasts (MDS-EB).
Learn more about MDS on the Together by St. Jude™ online resource.
Children with some types of MDS, such as RCC, may not need treatment other than close monitoring. RCC can worsen or progress to MDS-EB. In some cases, MDS can develop into acute myeloid leukemia (AML).
The most effective treatment for most types of MDS is an allogeneic bone marrow (stem cell) transplant. Chemotherapy may be used to treat patients with MDS, MDS-EB, or patients who have developed AML.
Other treatments for MDS include medicines to help the bone marrow make new blood cells and antibiotics to prevent or treat infections. Red blood cell and platelet transfusions can help with symptoms of anemia and bleeding.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults for myelodysplastic syndromes.
Study goal:
This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.
Age:
1-22 years old
Study goal:
The purpose of this study is to find the highest dose of CD70+ CAR cells that is safe to give to patients with CD70+ blood cancers.
Age:
Up to 21 years old
Study goal:
The primary objective of this study is to examine the incidence of neutrophil recovery after cord transplantation.
In participants receiving a non-licensed CBU: 1) to determine the frequency of graft rejection; 2) to determine the frequency of infection; 3) to determine the frequency of serious infusion reactio; 4) to determine the 1 year survival rate.
Study goal:
To find the safest dose of imetelstat that can be given with fludarabine and cytarabine to stop the growth of cancer cells.
Age:
Between 12 months and 18 years old
St. Jude provides the highest quality of care for patients with MDS:
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334